LABS vs. THRL, IHR, MXF, AGR, PHP, HWG, PRSR, MLI, WHR, and RDI
Should you be buying Life Science REIT stock or one of its competitors? The main competitors of Life Science REIT include Target Healthcare REIT (THRL), Impact Healthcare REIT (IHR), Medicx Fund (MXF), Assura (AGR), Primary Health Properties (PHP), Harworth Group (HWG), Prs Reit (PRSR), Industrials REIT (MLI), Warehouse REIT (WHR), and Rdi Reit (RDI). These companies are all part of the "real estate" sector.
Life Science REIT vs. Its Competitors
Life Science REIT (LON:LABS) and Target Healthcare REIT (LON:THRL) are both small-cap real estate companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Target Healthcare REIT has higher revenue and earnings than Life Science REIT. Life Science REIT is trading at a lower price-to-earnings ratio than Target Healthcare REIT, indicating that it is currently the more affordable of the two stocks.
Life Science REIT pays an annual dividend of GBX 2 per share and has a dividend yield of 4.5%. Target Healthcare REIT pays an annual dividend of GBX 6 per share and has a dividend yield of 5.9%. Life Science REIT pays out -17.7% of its earnings in the form of a dividend. Target Healthcare REIT pays out 50.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Life Science REIT has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500. Comparatively, Target Healthcare REIT has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500.
67.3% of Life Science REIT shares are owned by institutional investors. Comparatively, 69.4% of Target Healthcare REIT shares are owned by institutional investors. 7.0% of Life Science REIT shares are owned by insiders. Comparatively, 0.1% of Target Healthcare REIT shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Target Healthcare REIT's average media sentiment score of 0.20 beat Life Science REIT's score of 0.00 indicating that Target Healthcare REIT is being referred to more favorably in the news media.
Target Healthcare REIT has a net margin of 104.99% compared to Life Science REIT's net margin of -198.99%. Target Healthcare REIT's return on equity of 10.78% beat Life Science REIT's return on equity.
Life Science REIT presently has a consensus target price of GBX 46.50, suggesting a potential upside of 5.44%. Given Life Science REIT's stronger consensus rating and higher possible upside, analysts clearly believe Life Science REIT is more favorable than Target Healthcare REIT.
Summary
Target Healthcare REIT beats Life Science REIT on 12 of the 17 factors compared between the two stocks.
Get Life Science REIT News Delivered to You Automatically
Sign up to receive the latest news and ratings for LABS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Life Science REIT Competitors List
Related Companies and Tools
This page (LON:LABS) was last updated on 7/8/2025 by MarketBeat.com Staff
Free LABS Stock Alerts